Clinical Trial Detail

NCT ID NCT03318562
Title A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Effector Therapeutics
Indications

hepatocellular carcinoma

triple-receptor negative breast cancer

Therapies

Tomivosertib

Age Groups: adult senior

No variant requirements are available.